Forus announced a $150 million Series C on September 8 for software that handles the administrative work between a doctor writing a prescription and a patient obtaining the medicine. Medical practices use it to pursue insurance coverage, coordinate financial assistance and route prescriptions to pharmacies. The company is not discovering drugs or replacing the clinician's treatment decision. It is trying to make the existing delivery process easier to navigate.
A practice begins with an electronic prescription. Forus can prepare and submit prior authorization forms, the requests insurers require before covering some treatments, then track approvals or denials. Staff can follow the case in a dashboard and review an appeal when needed. The patient receives updates by text, while the prescription goes to the appropriate pharmacy for collection or delivery. Forus's patient guide explicitly says it is not itself a pharmacy.
Virginia Rheumatology Clinic offers a concrete example. In a company-published case study, the Chesapeake practice describes using Forus to track access to specialty medicines, see denial letters and follow the next step without repeatedly calling payers and pharmacies. Its physician, Brinda Dixit, reports that approvals often arrive in under two days, while staff describe fewer status calls. Those are attributed experiences from one practice, not independently measured results across every Forus customer.
Doctors and patients can use Forus free of charge, according to its product documentation. The broader business also works with biopharma companies on drug development and launches: identifying where access breaks down and connecting the organizations involved in getting a treatment to patients. Forus says nine of the largest 15 global biopharma companies work with it. That is a company-reported relationship count, not a disclosure of contract revenue or a claim that those partners finance individual prescriptions.
Bain Capital Ventures led the financing at a $3 billion valuation, with existing institutional backers including Thrive Capital, General Catalyst and Accel reinvesting. Forus says the round brings total funding above $300 million. The company began in 2023 under the Tandem name, as Forbes reported in May, and rebranded earlier this year. The new financing is separate from the $160 million cumulative funding figure it disclosed at that earlier launch.
The challenge is handling exceptions, not simply producing forms faster. A patient's coverage, clinical history, assistance eligibility and pharmacy requirements can point to different next steps, and the software operates across organizations it does not control. Forus's next stage will depend on keeping those handoffs reliable as more practices use the network. A completed administrative task only matters if the prescription continues toward the patient without creating another delay.